Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The FOCUS trial (NCT03811561), which is being conducted to study the long-term effects of semaglutide in diabetic eye disease, is ongoing and is expected to end in 2027
The NHS spends billions every year treating obesity-related illness
Some are FDA-approved for weight loss and others are approved as treatments for diabetes but can be used off-label for weight loss
During the maintenance phase (weeks 21-68), weight loss accelerates to 2-3 pounds per week on average, cumulative weight loss reaches 20-25% by week 68, body gains continue to build up, and quality of life gains become more pronounced
US$ 26.83
US$ 21.23
US$ 21.99
US$ 22.47
US$ 25.10
